RESUMEN

Mensaje

El asma es un problema de salud de gran importancia a nivel mundial. En algunos países, como Nueva Zelanda, su prevalencia llega a superar el 25%. En México no tenemos datos confiables acerca de su frecuencia en la población, pero sabemos que alrededor del 8% de los niños presentan este padecimiento.
Desgraciadamente, el diagnóstico y manejo del asma son heterogéneos y en muchos casos inadecuados, con la consiguiente disminución en la calidad de vida y aumento en el costo económico, el sufrimiento, y la mortalidad.
Ante la gravedad del problema, en diferentes países y Asociaciones se han formado grupos de trabajo para la elaboración de Consensos basados en la evidencia actual, que sirvan como guía para el diagnóstico y manejo. Ejemplo de estos Consensos son las Guías del Reino Unido, Canadá, Estados Unidos de América, la Unión Internacional Contra la Tuberculosis y las Enfermedades Respiratorias (UICTER) y las de la Iniciativa Global para el Asma (GINA).

PALABRAS CLAVE

.

REFERENCIAS

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Global Initiative for Asthma (GINA) Program. Allergy 2004.

2. The Global Burden of Asthma Report. GINA 2004. Página electrónica: www.ginasthma.org

3. ISAAC Steering Committee. Worldwide variations in the prevalence of asthma symptoms. Eur Respir J 1998; 12:315-3352.

4. Brogger J, Bakke P, Eide GE, Johansen B, Andersen A, Gulsvik A. Long-term changes in adult asthma prevalence. Eur Respir J, 2003; 21: 468-72.

5. Canseco C, de Hernández L, González SN, Zepeda H, Galindo G. Epidemiología de las enfermedades alérgicas en el área metropolitana de Monterrey. Revista Alergia (Mex) 1991; 38: 95-101.

6. Canseco C, Gonzalez SN, Alvarado C. Mortalidad por asma en el estado de Nuevo León, México. Revista Alergia (Mex) 1993; 40:119-123.

7. Mendoza A. Prevalencia de asma en Hermosillo, Sonora, México. Gac Méd Mex 2001; 137: 394-401.

8. Neffen H, Baena-Cagnani CE, Malka S, Sole D, Sepúlveda R, Caraballo L, Carbajal E, Rodríguez R, Gavida S, González-Díaz S, Guggiari J, Díez C, Baluga J, Hultett C. J invest Allergol Clin Immunol 1997; 7: 249-253.

9. Vargas MH y col. Aspectos epidemiológicos del asma infantil en México. Gac Méd Méx 1996; 132: 255-265.

10. Vargas MH, Díaz-Mejía G, Furuya M, Salas J, Lugo A. Trends of asthma in Mexico. An 11-year analysis in a nationwide institution. Chest 2004; 125: 1993-1997.

11. Informes sobre la salud en el mundo. Organización Mundial de la Salud. 2000.

12. Cole C. Family history, dust mite exposure in early childhood, and risk for pediatric atopy and asthma. J Allergy Cin Immunol 2004; 114: 105-110.

13. Kauffmann F. Epidemiologic study of the genetics and environment of asthma, bronchial hiyper-responsiveness and atopy. Chest 2002; 121 (suppl): 27s.

14. Prince JE, Kheradman F, Cony DB. Immunological lung disease. J Allergy Clin Immunol 2003; 111 (2 suppl): S613-S623.

15. Barnes KC. Atopy and asthma genes-where do we stand? Allergy 2000; 55(9): 803-817.

16. Doull IJ, Lawrence S, Watson M, Begishvili T, Beasley RW, Lampe F, Holgate T, Morton NE. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyper-responsiveness. Am J Respir Crit Care Med 1996; 153: 1280-4.

17. González BE, Avila P, Sylvette N, Elad Z, Casal J, Torres A, Rodriguez-Santana JR, Toscano M, Jody S, Alioto ME, Salazar M, Gomez I, Fagan JK, Matallana H, Castro R, Selman M, Chapela R, Sheppard D, Homer A, Boushey, Silverman EK. Lower Bronchodilator Responsiveness in Puerto Rican than in Mexican Asthmatic Subjects from the Genetics of Asthma in Latino Americans (GALA) Study. Am J Respir Crit Care Med 2004; 169: 386-392.

18. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the management of asthma. Thorax 2003; 58 (Suppl 1): 1-94.

19. Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P, on behalf of the Canadian Asthma Consensus Group. Canadian astma consensus report. Can Med Assoc J 1999; 11 supl: S1-S62.

20. Global Initiative for Asthma. Global strategy for asthma management and prevention. Update 2003. NIH Publication 02-3659 (update 2003).

21. National asthma education and prevention program. Guidelines for the diagnosis and management of asthma. Expert panel report 2, NIH Publication 1997; 97-4051.

22. Aït-Khaled N, Enarson D. El manejo del asma en los adultos. Guía para países con escasos recursos económicos. Publicación de la Unión Internacional Contra la Tuberculosis y las Enfermedades Respiratorias (UICTER). París, Francia, 1996.

23. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807.

24. Rabe KF. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.

25. Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. Chest 1993; 103(6): 1662-9.

26. American Thoracic Society. Standarization of spirometry. 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.

27. Pérez PR, Regalado J, Rojas M, Catalán M, Mendoza L, Rojas R, Chapela R, Villalba J, Torres V, Borja-Aburto V, Olaiz G. Spirometric function in children of Mexico City compared to mexican-american children. Pediatric Pulmonology 2003; 35: 177-183.

28. Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001; 17: 589-595.

29. Man-Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, The GOAL Investigators Group. Can Guideline-defined Asthma Control be Achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med. 2004; Jul 15 [Epub ahead of print].

30. Lim KG. Management of persistent symptoms in patients with asthma. Mayo Clin Proc 2002; 77: 1333-8.

31. Salas-Hernandez J, Ramírez-Venegas A, Carrillo G, Pérez-Chavira R, Sansores R, Mejía M, Chapela R. La conducta de un grupo de médicos mexicanos ante el diagnóstico y tratamiento del asma. Rev Inst Nal Enf Respir (Mex) 1994; 7: 116-121.

32. Beker A, Watson W, Ferguson A, Dimich-Ward H, Chag-Yeung M. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol 2004; 113: 650-656.

33. Huss K, Travis P, Huss RW. General principles of asthma management: environmental control. Nurs Clin North Am 2003; 38: 609-20.

34. Simpson A, Costovic A. Allergen avoidance in the primary prevention of asthma. Curr Opin Allergy Clin Immunol 2004; 4: 45-51.

35. Hernández M, Salmen S, Berrueta L, Navas M, Sanchez B, Muñoz J, et al. Control of inhaled triggering factors decreases prolonged drug therapy requirements in patients with asthma. Invest Clin 2000; 41: 3-18.

36. Saglani S, McKenzie SA. Environmental factors relevant to difficult asthma. Paediatr Respir Rev 2002; 3: 248-5431.

37. García Martínez J. Importance of environmental and preventive measures in the control of asthma in the child. Allergol Immunopathol 2000; 28: 158-62.

38. Evans R 3rd. Environmental control and immunotherapy for allergic disease. J Allergy Clin Immunol 1992; 90: 462-8.

39. Fischer GB, Fischer GB; Camargos PA. Paediatric asthma management in developing countries. Paediatr Respir Rev 2002; 3(4): 285-291.

40. Briening E. Management of children in status asthmaticus. Crit Care Nurse 1998; 18: 74-83.-51.

41. Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur Respir J 2002; 19(5): 892-898.

42. Bjorksten B. Unmet needs in the treatment of asthmatic children and adolescents: 2. Clin Exp Allergy 2000; 30 Suppl 1: 73-6.

43. Childhood Asthma Management Program Research Group. Design Paper. The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. NHLBI/Division of Lung Diseases. Controlled Clinical Trials 1999; 20: 91-120.

44. Akinbami L, Schoendorf K. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 2002; 110: 315-322.

45. Bender BG, Ellison MC, Gleasson M, Murphy JR, Sundstrom DA, Szelfler SJ. Minimizing attrition in a long-term clinical trial of pediatric asthma. Ann Allergy Asthma Immunol 2003; 91: 168-176.

46. Mcdowell KM, Chatburn RL, Myers TR, et al. A cost-saving algorithm for children hospitalized for status asthmaticus. Arch Paediatr Adolesc Med 1998; 152: 977-84.

47. Schuh S, Jonson D, Stephens D, et al. Hospitalization patterns in severe acute asthma in children. Pediatr Pulmonol 1997; 23: 184-92.

48. Gentile NT, Ufberg J, Barnum M, McHugh M, Karras D. Guidelines reduce X-ray and blood gas utilization in acute asthma. Am J Emerg Med 2003; 21: 451-453.

49. Cates CJ, Rowe BH, Bara A. Holding chambers versus nebulizer for beta-agonist treatment of acute asthma (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford. Update Software, 2001: 12.

50. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997; 157: 1736-44.

51. León MH, Flores-Murrieta FJ, Chapela Mendoza R. Assessment of Comparative Bioequivalence of two metered-Dose Inhaler Formulations of Salbutamol. Measuring Bronchodilatory Effect in Patients with Asthma. Clin Drug Invest 2002; 22(7): 435-441.

52. Wright RO, Santucci KA, Jay GD, et al. Evaluation of pre-and post-treatment pulse oximetry in acute childhood asthma. Acad Emerg Med 1997; 4: 114-7.

53. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Berthke T, Wurst W. The new phosphodiesterase 4 inhibitor Roflumilast is efficacious in exercise induced asthma and leades to suppresion of LPS-stimulated TNF alpha ex vivo. J Clin Pharmacol 2002; 42: 297-303.

54. Schmidt BM, Kusma M, Feuring M, Timmer WE, Neuhauser M, Bethke T, Stuck BA, Hormann K, Wehling M. The phosphodiesterases 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108: 530-536.

55. Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics 2003; 112: 382-97.

56. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA 1988; 260: 527-9.

57. Becker JM, Arora A, Scarfone RJ, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 1999; 103: 586-90.

58. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from emergency department. A randomized controlled trial. JAMA 1999; 281: 2119-26.

59. Rowe BH, Spooner CH, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids (Cochrane Review). In: The Cochrane Library. Issue 3, Oxford. Update Software, 2001: 26.

60. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000; 343: 689-694.

61. Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide to frequent high dose albuterol therapy in severe childhood asthma. J Pediatric 1995; 126: 639-45.

62. Lanes SF, Garrett JE, Wentworth CE 3rd, Fitzgerald JM, Karpel JP. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998; 114: 365-72.

63. Goodman DC, Littenberg B, O‘Connor GT, et al. Theophylline in acute childhood asthma. a meta-analysis of its efficacy. Pediatr Pulmonol 1996; 21: 211-46.

64. Parameswaran K, Belda J, Rowe BH. Adittion of intravenous aminophylline to beta2-agonists in adults with acute asthma (Cochrane Review). In: The Cochrane Library. Issue 3, Oxford. Update Software, 2001.

65. Ciarallo L, Brousseau D, Reinert S. Higher dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med 2000; 154: 979-83.

66. Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating asthma exacerbations. A metaanalysis of randomized clinical trials. Ann Emerg Med 1999; 34: 8-18.

67. Ho AM. Heliox vs air-oxigen mixtures for the treatment of patients with acute asthma. Chest 2003; 123: 882-890.

68. National Asthma Education and Prevention Program. Use of antibiotics to treat asthma exacerbations. Am Fam Physician 2003; 68: 1426, 1429-30, 1433.

69. Bergmann KC. Sports and allergy. Int J Sports Med 1991; 12 Suppl 1: 516-518.

70. Richter K, Janicki S, Jorres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002; 19(5): 865-71.

71. Spooner C, Rowe BH, Saunders LD. Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis. Eur Respir J 2000 Jul; 16(1): 30-7.

72. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28(4): 717-22.

73. American Thoracic Society. Guidelines for assessing and managing asthma risk at work, school, an recreation. Am J Resp Crit Care Med 2004; 169: 873-8.

74. Kogevinas M, Anto JM, Soriano JB, Tobias A, Burney P. The risk of asthma attributable to occupational exposures. A population-based study in Spain. Spanish Group of the European Asthma Study. Am J Respir Crit Care Med 1996 Jul; 154(1): 137-43.

75. Chan-Yeung M, Malo JL. Aetiological agents in occupational asthma. Eur Respir J 1994; 7(2): 346-71.

76. Ortega HG, Weissman DN, Carter DL, Banks D. Use of specific inhalation challenge in the evaluation of workers at risk for occupational asthma: a survey of pulmonary, allergy, and occupational medicine residency training programs in the United States and Canada. Chest 2002; 121(4): 1323-8.

77. Leynaert B. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004; 113: 86-93.

78. Cristal-Peters J. Treating Allergy rhinitis in patients with commorbid asthma: the risk of asthma related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109: 57-62.

79. Jaber R. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. Prim Care 2002; 29: 231-261.

80. Demissie K, Breckenridge MB, Rhoads CG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998; 158: 1095.

81. Perlow JH, Montgomery D, Morgan MA, et al. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 1992; 167: 963.

82. National Asthma Education Program: Report of the Working Group on Asthma and Pregnancy. Management of asthma during pregnancy. National Institutes of Health (NIH publication No. 93-3279A), Bethesda, MD, 1993.

83. Gardner MO, Doyle NM. Asthma in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 385-413.

84. Tamul PC. Assessment and management of patients with pulmonary disease. Crit Care Med 2004; 32 (4 suppl): 5137-5145.

85. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection results in airway hyper-responsiveness and enhanced airway sensitization to allergen. J Clin Invest 1997; 100(1): 226-33.

86. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 21; 344(25): 1917-28.

87. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.

88. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996; 97(1): 137-40.

89. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 61(5): 1501-7.

90. Pattemore PK, Johnston SL, Bardin PG. Viruses as precipitants of asthma symptoms. I. Epidemiology. Clin Exp Allergy 1992; 22(3): 325-36.

91. Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162(1): 34-9.

92. Coughlan JL, Gibson PG, Henry RL. Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review. Thorax 2001; 56(3): 198-204.

93. Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159(21): 2582-8.

94. Young SY, Gunzenhauser JD, Malone KE, McTiernan A. Body mass index and asthma in the military population of the northwestern United States. Arch Intern Med 2001; 161(13): 1605-11.

95. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002 Jul 8; 162(13): 1477-81.

96. Ehrlich RI, Du Toit D, Jordaan E, Zwarenstein M, Potter P, Volmink JA, Weinberg E. Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Am J Respir Crit Care Med 1996; 154: 681-8.

97. Radon K, Bürhing K, Heinrich J, Wichmann HE, Jörres RA, Magnussen H, Nowak D. Passive smoking exposure: a risk factor for chronic bronchitis and asthma in adults? Chest 2002; 122: 1086-1090.